- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06905470
Effektene av eksentrisk sammenlignet med standard styrketrening i primær rehabilitering av ryggmargsskader (KREHA3)
Effektene av eksentrisk sammenlignet med standard styrketrening i primær rehabilitering av ryggmargsskader - et samsvarende par randomisert kontrollert studie
The goal of this clinical trial is to assess the effects of eccentric arm-crank (KREHA) training compared to standard clinical routine strength (STAN) training in individuals undergoing primary spinal cord injury (SCI) rehabilitation.
The main questions this trail aims to answer are:
- what are the effects of the training on upper body strength, aerobic performance, muscle volume, functional independence, and health-related quality of life?
- is the KREHA training feasible to implement into the rehabilitation routine?
Participants will:
- perform either 20 KREHA sessions or 20 STAN sessions within 12 weeks
- perform a test battery to collect data on training effects before (pretest) and after (posttest) the study intervention
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Fabian Ammann, MSc
- Telefonnummer: +41419396624
- E-post: fabian.ammann@paraplegie.ch
Studer Kontakt Backup
- Navn: Anneke Hertig-Godeschalk, PhD
- Telefonnummer: +414 9396603
- E-post: anneke.hertig@paraplegie.ch
Studiesteder
-
-
Canton of Lucerne
-
Nottwil, Canton of Lucerne, Sveits, 6207
- Swiss Paraplegic Centre
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 18 years or older.
- informed consent as confirmed per signature.
- traumatic or disease-related SCI.
- participating in the routine strength training program during primary SCI rehabilitation at the study center (generally this is initiated around one month after SCI onset).
- wheelchair dependency during activities of daily living, defined by a score of 0-2 in the SCIM subsection regarding "Mobility in the house".
- passed sports medical assessment and having sufficient biceps/triceps function to perform arm-crank training, as determined by an experienced sports medicine physician
Exclusion Criteria:
- inflammatory or neurodegenerative diseases (including multiple sclerosis or Guillain-Barré syndrome).
- comorbidities or other health issues that may interfere with study participation, inability or contraindications to undergo the investigated intervention.
- MRI contraindications (magnetic metal parts or electronic implants such as pacemakers in the body).
- pregnancy (anamnestic).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Eccentric arm-crank (KREHA) training
The eccentric training intervention consists of 20 training sessions performed on a symmetric arm-crank (Krafttraining mittels exzentrischer Handkurbel, KREHA) device. The training sessions have a duration of approximately 30 min and will be completed within twelve weeks, with a maximum of three sessions per week. |
20 eccentric resistance training sessions will be performed on a symmetric arm-crank ergometer in a supine position. |
|
Aktiv komparator: Standard clinical routine strength (STAN) training
The standard strength training intervention consists of a total of 20 training sessions at the gym of the study center, performed following clinical routine procedures. The training sessions have a duration of approximately 60 min and will be completed within twelve weeks, with around three sessions per week. |
The regular strength training intervention consists of a total of 20 training sessions at the gym of the study center, performed following clinical routine procedures. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Upper body strength
Tidsramme: < 1 week pre and 12 weeks post intervention start.
|
Change in upper body strength will be measured by a one-repetition maximum (1RM) bench press (in kg). The maximum amount of weight that can be pushed upwards for one repetition, while lying in a supine position on a weight training bench. |
< 1 week pre and 12 weeks post intervention start.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Upper body strength
Tidsramme: < 1 week pre and 12 weeks post intervention start.
|
Change in upper body strength measured by a 1RM bench pull (in kg). The maximum amount of weight that can be pulled upwards for one repetition, while lying in a prone position on a weight training bench. |
< 1 week pre and 12 weeks post intervention start.
|
|
Handgrip strength
Tidsramme: < 1 week pre and 12 weeks post intervention start.
|
Change in maximum strength of three handgrip measurements (in kg) of both hands using a Jamar Handgrip Dynamometer. |
< 1 week pre and 12 weeks post intervention start.
|
|
Aerobic performance
Tidsramme: < 1 week pre and 12 weeks post intervention start.
|
Change in cardiopulmonary adaptations, measured by aerobic performance in an exercise test on a regular arm-crank ergometer. A ramp protocol starting at 20 Watt followed by 1 Watt / 6 sec increments to failure will be used. The following parameters will be evaluated during this aerobic endurance test: power at failure at the end of the test (in Watt), peak oxygen uptake during the test (in ml/kg/min), maximal heart rate (bpm) |
< 1 week pre and 12 weeks post intervention start.
|
|
Muscle volume
Tidsramme: < 1 week pre and 12 weeks post intervention start.
|
Magnetic resonance imaging (MRI) of relevant upper body muscles of the dominant upper arm and shoulder will be used to measure change in muscle volume. |
< 1 week pre and 12 weeks post intervention start.
|
|
Arm circumference
Tidsramme: < 1 week pre and 12 weeks post intervention start.
|
Change in arm circumference of the right and left lower and upper arm (in cm), will be used to estimate muscle volume. |
< 1 week pre and 12 weeks post intervention start.
|
|
Functioning during activities of daily living
Tidsramme: < 1 week pre and 12 weeks post intervention start.
|
Change in functioning during activities of daily living will be assessed by the Spinal Cord Independence Measure (SCIM) as extracted from clinical records. The SCIM total score ranges from 0-100, with higher scores indicating higher levels of functional independence. |
< 1 week pre and 12 weeks post intervention start.
|
|
Health-related quality of life
Tidsramme: < 1 week pre and 12 weeks post intervention start.
|
Change in health-related quality of life will be assessed using the Short Form Health Survey (SF-12). Weighted physical and mental component scores range from 0-100, with higher scores indicating better physical or mental health. |
< 1 week pre and 12 weeks post intervention start.
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility of the KREHA training (total number of training sessions)
Tidsramme: Throughout the intervention phase, week 0-12
|
Successful implementation of the KREHA training in the clinical routine, by assessing whether the 20 KREHA sessions are completed within 12 weeks. |
Throughout the intervention phase, week 0-12
|
|
Feasibility of the KREHA training progression (number of sessions adapted)
Tidsramme: Throughout the intervention phase, week 0-12
|
Feasibility of the KREHA training progression, by assessing how many training sessions needed to be adapted. |
Throughout the intervention phase, week 0-12
|
|
Feasibility of the KREHA training progression (power adaptation)
Tidsramme: Throughout the intervention phase, week 0-12
|
Feasibility of the KREHA training progression, by assessing how much the target power (in Watts) of a training session needed to be adapted compared to the initially planned progression. |
Throughout the intervention phase, week 0-12
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2023-21
- SNCTP000006132 (Annen identifikator: Swiss National Clinical Trials Portal)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .